Review explores the impact of an on-body injector for isatuximab delivery in multiple myeloma, suggesting improvements in patient care and clinical efficiency.
The use of an OBI for the delivery of SC isatuximab could potentially improve clinical workflow, reduce duration of clinical visits and physical burden for HCPs through hands-free administration, and enhance patient experience through the small, hidden needle.
No takes yet. Share an insight, caveat, or question.
Ocio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: